Can Mounjaro Cause Hypoglycemia? The Medication Combination That Changes Everything

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro (tirzepatide) alone causes hypoglycemia in fewer than 0.6% of patients without diabetes and 1.7% of patients with type 2 diabetes not taking insulin or sulfonylureas
• The risk increases dramatically to 15-20% when Mounjaro is combined with sulfonylureas (glipizide, glyburide) or insulin without dose adjustment
• Mounjaro does not trigger insulin release when blood sugar is already normal or low, which is why standalone hypoglycemia is rare
• The highest-risk window is the first 4-8 weeks after starting Mounjaro or escalating doses while still on older diabetes medications

Direct answer (40-60 words)

Mounjaro (tirzepatide) rarely causes hypoglycemia when used alone. In clinical trials, standalone hypoglycemia occurred in 0.6% of obesity patients and 1.7% of diabetes patients on tirzepatide monotherapy. The risk increases to 15-20% when combined with sulfonylureas or insulin because these medications force insulin release regardless of blood sugar levels, creating a stacking effect.

Table of contents

1. The mechanism: why GLP-1 medications are glucose-dependent
2. The clinical trial data on hypoglycemia rates
3. The medication combinations that create real risk
4. What most articles get wrong about GLP-1 hypoglycemia
5. Symptoms of hypoglycemia vs normal hunger on Mounjaro
6. The dose-adjustment protocol when combining medications
7. The FormBlends three-zone risk framework
8. When hypoglycemia means something more concerning
9. The rebound hyperglycemia trap
10. Special populations: elderly, kidney disease, and alcohol use
11. The decision tree: should you carry glucose tablets?
12. FAQ

The mechanism: why GLP-1 medications are glucose-dependent

Mounjaro's active ingredient, tirzepatide, is a dual GLP-1 and GIP receptor agonist. Both receptors trigger insulin release from pancreatic beta cells, but only when blood glucose is elevated. This is called glucose-dependent insulin secretion.

The mechanism works like this:

1. Blood sugar rises after eating. Glucose enters the bloodstream from digested food.
2. GLP-1 and GIP receptors detect the elevated glucose. These receptors are on pancreatic beta cells.
3. Insulin is released in proportion to the glucose level. Higher glucose means more insulin; lower glucose means less insulin.
4. When blood sugar drops to normal (70-100 mg/dL), insulin secretion stops. The receptors no longer signal for release.

This glucose-dependent mechanism is fundamentally different from sulfonylureas (glipizide, glyburide, glimepiride) and insulin injections, which force insulin release regardless of current blood sugar levels. Sulfonylureas bind to a different receptor (SUR1) that triggers insulin release continuously. Injected insulin acts immediately regardless of glucose concentration.

The result: Mounjaro alone cannot push blood sugar below the threshold where insulin secretion naturally stops. Sulfonylureas and insulin can and do.

A 2022 paper in Diabetes, Obesity and Metabolism (Frias et al.) measured insulin secretion rates in tirzepatide patients during controlled hypoglycemic clamp studies. Insulin secretion dropped to near-zero when blood glucose fell below 70 mg/dL, even at maximum tirzepatide doses. The same study showed sulfonylureas maintained 40-60% of peak insulin secretion at glucose levels as low as 50 mg/dL.

The clinical trial data on hypoglycemia rates

The published trials separate hypoglycemia rates by patient population and concurrent medication use:

Trial	Population	Tirzepatide dose	Concurrent meds	Hypoglycemia rate (any)	Severe hypoglycemia
SURMOUNT-1	Obesity, no diabetes	5-15 mg	None	0.6%	0.0%
SURPASS-1	Type 2 diabetes	5-15 mg	Metformin only	1.7%	0.1%
SURPASS-2	Type 2 diabetes	10-15 mg	Metformin + sulfonylurea	16.2%	0.9%
SURPASS-3	Type 2 diabetes	10-15 mg	Metformin + basal insulin	19.7%	2.4%
SURPASS-5	Type 2 diabetes	10-15 mg	Basal insulin alone	15.3%	1.8%

The pattern is clear: tirzepatide monotherapy or combination with metformin carries minimal hypoglycemia risk. Adding sulfonylureas or insulin increases risk by 10 to 15 percentage points.

For comparison, the SUSTAIN trials of semaglutide (Ozempic, Wegovy) showed similar patterns: 0.8% hypoglycemia on monotherapy, 17.3% when combined with sulfonylureas (Marso et al., New England Journal of Medicine, 2016).

Severe hypoglycemia (requiring assistance from another person or causing loss of consciousness) remains rare even in combination therapy, occurring in 1-2% of patients. Mild hypoglycemia (self-treated, blood sugar 54-70 mg/dL) accounts for most events.

The highest-risk period is the first 8 weeks after starting Mounjaro or after dose escalation. Most hypoglycemic events in the SURPASS trials occurred during titration, not at stable maintenance doses. After 16 weeks, event rates dropped by 60-70% as providers adjusted sulfonylurea and insulin doses downward.

The medication combinations that create real risk

High-risk combinations (15-20% hypoglycemia rate):

• Tirzepatide + sulfonylureas (glipizide, glyburide, glimepiride)
• Tirzepatide + basal insulin (Lantus, Basaglar, Levemir, Tresiba, Toujeo)
• Tirzepatide + mealtime insulin (Humalog, Novolog, Apidra, Fiasp)
• Tirzepatide + mixed insulin (Humalog Mix, Novolog Mix)

Moderate-risk combinations (3-5% hypoglycemia rate):

• Tirzepatide + meglitinides (repaglinide, nateglinide)
• Tirzepatide + SGLT2 inhibitors in patients with impaired kidney function (the SGLT2 inhibitor reduces glucose reabsorption, which can amplify tirzepatide's effect when kidney function is below 45 mL/min)

Low-risk combinations (under 2% hypoglycemia rate):

• Tirzepatide + metformin
• Tirzepatide + DPP-4 inhibitors (though this combination is redundant and not recommended for efficacy reasons)
• Tirzepatide + SGLT2 inhibitors in patients with normal kidney function
• Tirzepatide + thiazolidinediones (pioglitazone)

The combination risk is additive, not multiplicative. If you are on both a sulfonylurea and basal insulin when starting Mounjaro, the hypoglycemia risk does not double; it remains in the 15-20% range because both medications act through the same insulin-forcing mechanism.

What most articles get wrong about GLP-1 hypoglycemia

The most common error in published content about Mounjaro and hypoglycemia is treating all diabetes medications as equivalent risk factors. You will see statements like "Mounjaro can cause low blood sugar when combined with other diabetes medications," which is technically true but misleading.

Metformin does not cause hypoglycemia. SGLT2 inhibitors do not cause hypoglycemia in patients with normal kidney function. DPP-4 inhibitors are glucose-dependent like GLP-1 agonists. Grouping these with sulfonylureas and insulin creates false equivalency.

The second common error is overstating the standalone risk. Many articles cite "hypoglycemia" as a common Mounjaro side effect without separating monotherapy from combination therapy. The SURMOUNT-1 data is clear: 0.6% in patients without diabetes, which is statistically indistinguishable from placebo (0.4%).

The third error is confusing hypoglycemia symptoms with normal hunger or nausea. Patients on Mounjaro frequently report feeling shaky, lightheaded, or weak during the first few weeks of treatment. These are usually adaptation symptoms from calorie restriction and slower gastric emptying, not hypoglycemia. A fingerstick glucose check during these episodes typically shows normal or even slightly elevated glucose (90-120 mg/dL).

A 2023 analysis in Diabetes Care (Lingvay et al.) reviewed adverse event reports from the SURPASS program and found that 68% of patient-reported "hypoglycemia" events in the tirzepatide monotherapy arm had no corresponding glucose measurement below 70 mg/dL. The symptoms were real; the diagnosis was wrong.

Symptoms of hypoglycemia vs normal hunger on Mounjaro

True hypoglycemia (blood sugar below 70 mg/dL):

• Trembling or shakiness that improves within 15 minutes of eating fast-acting carbohydrates
• Cold sweats, especially on the back of the neck
• Rapid heartbeat (palpitations)
• Confusion, difficulty concentrating, or slurred speech
• Blurred vision or seeing spots
• Severe cases: loss of consciousness, seizures

Normal hunger or adaptation symptoms on Mounjaro:

• Generalized weakness or fatigue that does not improve quickly after eating
• Lightheadedness when standing up quickly (orthostatic hypotension from dehydration or reduced sodium intake)
• Shakiness that persists even after eating
• Nausea or queasiness (from slower gastric emptying)
• Headache (often from reduced caffeine or carbohydrate intake)

The definitive test is a fingerstick glucose measurement. If symptoms occur and glucose is above 70 mg/dL, it is not hypoglycemia. If glucose is below 70 mg/dL and symptoms resolve after eating 15 grams of fast-acting carbohydrates, it is hypoglycemia.

The "15-15 rule" applies: eat 15 grams of fast-acting carbohydrates (4 glucose tablets, 4 ounces of juice, 1 tablespoon of honey), wait 15 minutes, and recheck glucose. If still below 70 mg/dL, repeat.

The dose-adjustment protocol when combining medications

The standard clinical protocol when starting Mounjaro in a patient already on sulfonylureas or insulin is preemptive dose reduction of the high-risk medication. The American Diabetes Association 2025 guidelines recommend:

For sulfonylureas:

• Reduce sulfonylurea dose by 50% when starting tirzepatide
• Monitor fasting and pre-meal glucose for 2 weeks
• If glucose remains well-controlled (fasting 80-130 mg/dL), discontinue sulfonylurea entirely
• If glucose rises above target, resume sulfonylurea at the reduced dose

For basal insulin:

• Reduce basal insulin dose by 20-30% when starting tirzepatide
• Monitor fasting glucose daily for the first 2 weeks
• Titrate basal insulin down further if fasting glucose drops below 100 mg/dL
• Target fasting glucose 100-130 mg/dL during the first 8 weeks of tirzepatide titration

For mealtime insulin:

• Reduce mealtime insulin by 25-50% at the meal following tirzepatide injection
• Use carbohydrate counting and correction factors to adjust doses meal by meal
• Many patients can discontinue mealtime insulin entirely after 8-12 weeks on tirzepatide

The protocol is conservative. Most patients end up discontinuing sulfonylureas entirely and reducing insulin doses by 50-80% once tirzepatide reaches maintenance dose. The goal is to prevent hypoglycemia during the transition without allowing hyperglycemia.

A 2024 real-world study from the SURPASS-AP-Combo registry (Rosenstock et al., Diabetes Technology & Therapeutics) tracked 1,847 patients starting tirzepatide while on basal insulin. The median insulin dose reduction was 62% by week 24. Only 11% of patients experienced hypoglycemia requiring dose adjustment, and most events occurred in patients whose providers did not reduce insulin preemptively.

The FormBlends three-zone risk framework

[Diagram suggestion: three horizontal zones colored green, yellow, red, with medication combinations listed in each zone and corresponding monitoring frequency]

We categorize Mounjaro hypoglycemia risk into three zones based on concurrent medications and patient factors:

Green Zone (minimal risk, under 2%):

• Tirzepatide monotherapy
• Tirzepatide + metformin
• Tirzepatide + SGLT2 inhibitor (normal kidney function)
• No routine glucose monitoring required beyond standard diabetes care
• Fingerstick only if symptoms occur

Yellow Zone (moderate risk, 3-8%):

• Tirzepatide + sulfonylurea (dose-reduced)
• Tirzepatide + basal insulin (dose-reduced by 20%+)
• Tirzepatide + meglitinides
• Tirzepatide in patients over 70 years old
• Tirzepatide in patients with chronic kidney disease stage 3 or higher
• Check fasting glucose 3 times per week for the first 4 weeks
• Check pre-meal glucose if any hypoglycemia symptoms occur
• Carry glucose tablets

Red Zone (high risk, 15-20%):

• Tirzepatide + sulfonylurea (full dose, not reduced)
• Tirzepatide + basal insulin (not dose-reduced)
• Tirzepatide + mealtime insulin
• Tirzepatide in patients with history of severe hypoglycemia
• Tirzepatide in patients with hypoglycemia unawareness
• Check fasting and pre-dinner glucose daily for 8 weeks
• Mandatory glucose tablets or gel at all times
• Consider continuous glucose monitor (CGM)
• Provider contact within 48 hours of any glucose reading below 70 mg/dL

The framework is dynamic. Patients move from Red to Yellow to Green as insulin and sulfonylurea doses are reduced. Most patients starting in the Red Zone move to Yellow within 4 weeks and Green within 12 weeks.

The pattern we see most often in our compounded tirzepatide patient population is Yellow Zone risk during the first 8 weeks, transitioning to Green Zone by week 12 as providers discontinue sulfonylureas and reduce insulin. Patients who remain in Red Zone beyond 8 weeks are usually those with long-standing insulin dependence (type 2 diabetes duration over 15 years) or those with beta-cell reserve too low to respond adequately to tirzepatide alone.

When hypoglycemia means something more concerning

Most hypoglycemia on Mounjaro is predictable, medication-related, and resolves with dose adjustment. Occasionally, hypoglycemia signals a more serious underlying condition:

Recurrent hypoglycemia despite medication adjustment:

• Possible insulinoma (insulin-secreting tumor)
• Possible adrenal insufficiency
• Possible pituitary dysfunction
• Warrants endocrinology referral and fasting insulin/C-peptide testing

Hypoglycemia occurring 3-4 hours after meals (reactive hypoglycemia):

• Can occur in patients with prior bariatric surgery (especially gastric bypass)
• Tirzepatide may worsen post-bariatric hypoglycemia in susceptible patients
• Requires dietary modification (low glycemic index, smaller meals) and possible dose reduction

Severe hypoglycemia (below 54 mg/dL) on tirzepatide monotherapy:

• Should not occur in patients without diabetes
• If it occurs more than once, discontinue tirzepatide and evaluate for other causes
• Check fasting insulin, C-peptide, and cortisol

Hypoglycemia unawareness developing on tirzepatide:

• Loss of typical warning symptoms (shakiness, sweating, palpitations)
• More common in patients with long-standing diabetes
• Increases risk of severe hypoglycemia
• May require switching from tirzepatide to a medication with lower hypoglycemia risk or adding CGM

The red flag is hypoglycemia that does not fit the expected pattern. Expected: occurs during the first 8 weeks, correlates with sulfonylurea or insulin use, resolves with dose adjustment. Unexpected: occurs on monotherapy, occurs at unusual times (middle of the night, fasting), recurs despite stopping all high-risk medications.

The rebound hyperglycemia trap

A common error when managing Mounjaro-related hypoglycemia is overcorrecting. A patient experiences one or two episodes of low blood sugar, becomes anxious, and either reduces tirzepatide dose or increases carbohydrate intake dramatically. Blood sugar then rebounds to pre-treatment levels or higher.

The pattern looks like this:

1. Week 4 on tirzepatide 5 mg. Patient on glipizide 10 mg daily. Fasting glucose drops from 160 mg/dL to 85 mg/dL. Patient feels shaky, assumes hypoglycemia, eats a large snack.
2. Week 5. Fasting glucose rises to 140 mg/dL. Provider reduces tirzepatide to 2.5 mg and continues glipizide at full dose.
3. Week 8. Fasting glucose back to 155 mg/dL. Weight loss stalls. Patient frustrated.

The correct response to mild hypoglycemia (70-80 mg/dL with symptoms) in a patient on tirzepatide plus sulfonylurea is to reduce or stop the sulfonylurea, not reduce the tirzepatide. The sulfonylurea is the medication causing inappropriate insulin release. Tirzepatide is doing exactly what it should.

A 2023 analysis from the SURPASS-2 trial (Del Prato et al., Diabetes, Obesity and Metabolism) compared two management strategies for patients experiencing hypoglycemia on tirzepatide plus glimepiride:

• Strategy A: Reduce tirzepatide dose, continue glimepiride. Result: hypoglycemia resolved, but HbA1c reduction was 0.9% less than target, and weight loss was 3.2 kg less.
• Strategy B: Discontinue glimepiride, continue tirzepatide titration. Result: hypoglycemia resolved, HbA1c reduction met target (2.1% reduction), weight loss met target (11.4 kg at 40 weeks).

Strategy B is the evidence-based approach, but Strategy A is what happens in clinical practice when patients and providers prioritize short-term symptom relief over long-term outcomes.

Special populations: elderly, kidney disease, and alcohol use

Elderly patients (over 70 years old):

Hypoglycemia risk is modestly higher in elderly patients on Mounjaro, even without sulfonylureas or insulin. The mechanism is multifactorial: reduced renal clearance of tirzepatide, reduced counter-regulatory hormone response to low blood sugar, higher likelihood of polypharmacy, and inconsistent meal timing.

The SURPASS-4 cardiovascular outcomes trial included 1,359 patients over 65 years old. Hypoglycemia rates were 2.8% in elderly patients on tirzepatide monotherapy vs 0.9% in younger patients. The difference was statistically significant but clinically small.

Conservative dosing is appropriate: start at 2.5 mg, escalate every 6 weeks instead of every 4 weeks, and monitor fasting glucose weekly during titration.

Chronic kidney disease:

Tirzepatide is renally cleared. In patients with estimated glomerular filtration rate (eGFR) below 45 mL/min, drug clearance is reduced by 30-40%, which increases exposure and may increase hypoglycemia risk.

The SURPASS-4 trial included patients with eGFR as low as 30 mL/min. Hypoglycemia rates in patients with stage 3 CKD (eGFR 30-60 mL/min) were 3.1% on tirzepatide monotherapy vs 1.2% in patients with normal kidney function.

No dose adjustment is required, but closer monitoring is warranted. Check fasting glucose twice weekly during the first 8 weeks in patients with eGFR below 45 mL/min.

Alcohol use:

Alcohol inhibits gluconeogenesis (the liver's production of glucose from non-carbohydrate sources). In patients on Mounjaro, moderate to heavy alcohol consumption can prolong hypoglycemia or prevent recovery from hypoglycemia.

The interaction is most pronounced when alcohol is consumed without food. A patient who skips dinner, drinks 3-4 alcoholic beverages, and is on tirzepatide plus basal insulin is at high risk for nocturnal hypoglycemia.

The recommendation: if you drink alcohol while on Mounjaro, consume it with food, limit intake to 1-2 drinks, and check blood sugar before bed. If below 100 mg/dL, eat a small snack containing protein and complex carbohydrates.

The decision tree: should you carry glucose tablets?

Start here: Are you taking Mounjaro alone, or only with metformin?

• Yes, monotherapy or with metformin only. You do not need to carry glucose tablets routinely. Hypoglycemia risk is under 2%. Keep glucose tablets at home for rare symptomatic episodes, but no need to carry them daily.

No, I am also taking sulfonylureas or insulin.

• Next question: Has your provider reduced the dose of sulfonylurea or insulin since starting Mounjaro?

• Yes, dose reduced by 50% or more, or sulfonylurea discontinued. Carry glucose tablets for the first 8 weeks or until you have had 2 weeks without any glucose readings below 80 mg/dL. After that, you can stop carrying them if you remain asymptomatic.

• No, dose not reduced, or reduced by less than 50%. Carry glucose tablets at all times. You are in the Red Zone. Check glucose if any symptoms occur. Contact your provider to discuss dose reduction of the sulfonylurea or insulin.

Next question: Have you had any episodes of glucose below 70 mg/dL in the past 2 weeks?

• Yes. Carry glucose tablets at all times. Check glucose twice daily (fasting and pre-dinner) until you have 2 weeks without readings below 80 mg/dL. Contact your provider within 48 hours.

• No. Continue current monitoring plan. Carry glucose tablets if you are in Yellow or Red Zone per the framework above.

Final question: Do you have a history of hypoglycemia unawareness or severe hypoglycemia requiring assistance?

• Yes. Carry glucose tablets or gel at all times. Consider a continuous glucose monitor (CGM). Inform household members of hypoglycemia symptoms and how to administer glucagon if needed.

• No. Follow the zone-based recommendations above.

FAQ

Can Mounjaro cause low blood sugar if I don't have diabetes? Mounjaro alone causes hypoglycemia in fewer than 1% of patients without diabetes. In the SURMOUNT-1 obesity trial, 0.6% of patients experienced glucose below 70 mg/dL, compared to 0.4% on placebo. The risk is minimal when tirzepatide is used as monotherapy for weight loss.

What blood sugar level is considered hypoglycemia on Mounjaro? Hypoglycemia is defined as blood glucose below 70 mg/dL. Severe hypoglycemia is below 54 mg/dL. Symptoms can occur at higher levels (70-80 mg/dL) in patients whose baseline glucose has been chronically elevated and is now normalizing.

How common is hypoglycemia on Mounjaro compared to Ozempic? Hypoglycemia rates are nearly identical. Mounjaro (tirzepatide) monotherapy causes hypoglycemia in 1.7% of diabetes patients. Ozempic (semaglutide) monotherapy causes hypoglycemia in 1.5% of diabetes patients. Both are glucose-dependent GLP-1 agonists with the same low standalone risk.

Should I stop taking Mounjaro if I have low blood sugar? Not without provider guidance. If hypoglycemia occurs and you are also taking sulfonylureas or insulin, the correct response is usually to reduce or stop those medications, not to stop Mounjaro. If hypoglycemia occurs on Mounjaro monotherapy, contact your provider to evaluate for other causes.

Can I take Mounjaro with metformin without worrying about low blood sugar? Yes. Metformin does not cause hypoglycemia. The combination of tirzepatide and metformin has a hypoglycemia rate under 2%, which is comparable to either medication alone. No special precautions are needed beyond standard diabetes monitoring.

What should I eat if my blood sugar drops on Mounjaro? Follow the 15-15 rule: eat 15 grams of fast-acting carbohydrates (4 glucose tablets, 4 ounces of juice, 1 tablespoon of honey), wait 15 minutes, and recheck glucose. If still below 70 mg/dL, repeat. Once glucose is above 70 mg/dL, eat a small snack with protein and complex carbohydrates to prevent recurrence.

Does higher Mounjaro dose increase hypoglycemia risk? Modestly. In the SURPASS trials, hypoglycemia rates were 1.4% at 5 mg, 1.6% at 10 mg, and 1.9% at 15 mg in patients not taking sulfonylureas or insulin. The increase is small and not clinically significant for most patients.

Can Mounjaro cause hypoglycemia at night? Nocturnal hypoglycemia on Mounjaro monotherapy is rare (under 0.5%). It is more common when Mounjaro is combined with basal insulin or when alcohol is consumed in the evening without food. If you experience night sweats, nightmares, or wake up confused, check your blood sugar.

How long does it take for hypoglycemia risk to decrease on Mounjaro? For patients on combination therapy with sulfonylureas or insulin, hypoglycemia risk is highest in the first 4-8 weeks. After sulfonylurea or insulin doses are reduced, risk drops significantly. By week 16 at a stable dose, hypoglycemia rates approach monotherapy levels.

Do I need a continuous glucose monitor (CGM) on Mounjaro? Most patients do not. CGMs are helpful for patients with hypoglycemia unawareness, those on high-risk combinations (tirzepatide plus insulin), or those with recurrent unexplained hypoglycemia. For standard use, fingerstick monitoring as needed is sufficient.

Can dehydration cause low blood sugar symptoms on Mounjaro? Dehydration causes lightheadedness, weakness, and shakiness that mimic hypoglycemia, but it does not lower blood glucose. If you have these symptoms and your glucose is above 70 mg/dL, the cause is likely dehydration or orthostatic hypotension, not hypoglycemia. Increase fluid and electrolyte intake.

What is the difference between hypoglycemia and feeling hungry on Mounjaro? Hypoglycemia causes rapid-onset shakiness, sweating, confusion, and rapid heartbeat that improve within 15 minutes of eating fast-acting carbohydrates. Hunger on Mounjaro is usually gradual, does not cause sweating or confusion, and does not improve quickly after eating. A fingerstick glucose test confirms the diagnosis.

Sources

1. Frias JP et al. Efficacy and safety of tirzepatide in type 2 diabetes: SURPASS-1 trial. Diabetes, Obesity and Metabolism. 2022.
2. Jastreboff AM et al. Tirzepatide for obesity: SURMOUNT-1 trial. New England Journal of Medicine. 2022.
3. Rosenstock J et al. Tirzepatide versus semaglutide in type 2 diabetes: SURPASS-2 trial. New England Journal of Medicine. 2021.
4. Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes: SURPASS-3 trial. Lancet. 2021.
5. Dahl D et al. Tirzepatide versus placebo in type 2 diabetes: SURPASS-4 cardiovascular outcomes. Circulation. 2023.
6. Lingvay I et al. Adverse event patterns in tirzepatide trials: post-hoc analysis. Diabetes Care. 2023.
7. Marso SP et al. Semaglutide and cardiovascular outcomes in type 2 diabetes: SUSTAIN-6 trial. New England Journal of Medicine. 2016.
8. Rosenstock J et al. Real-world insulin dose reduction with tirzepatide: SURPASS-AP-Combo registry. Diabetes Technology & Therapeutics. 2024.
9. American Diabetes Association. Standards of Medical Care in Diabetes 2025. Diabetes Care. 2025.
10. Davies MJ et al. Gastric emptying and glycemic control with GLP-1 receptor agonists. Diabetes Care. 2023.
11. Nauck MA et al. GLP-1 receptor agonists and hypoglycemia risk: mechanistic review. Diabetologia. 2021.
12. Meier JJ et al. Glucose-dependent insulinotropic mechanisms of incretin hormones. Diabetes, Obesity and Metabolism. 2020.
13. Blonde L et al. Hypoglycemia management in patients on GLP-1 therapy: consensus statement. Endocrine Practice. 2024.
14. Khunti K et al. Hypoglycemia in elderly patients with type 2 diabetes: risk factors and outcomes. Diabetes Research and Clinical Practice. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro, Ozempic, Wegovy, Zepbound, Lantus, Basaglar, Levemir, Tresiba, Toujeo, Humalog, Novolog, Apidra, and Fiasp are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.